Month: November 2023

Make your savings profitable!

ROVI employees can take advantage of special offers when opening interest-bearing accounts and deposits at Banco Cooperativo Español:

• Enjoy the conditions of the Remunerated Account: Open an account with the amount you want in exchange for remuneration at a fixed interest rate.
• Special offer for opening a Fixed Term Deposit: Deposit the amount you want for six months or one year in exchange for a fixed interest rate.

Working at ROVI has its advantages

For more information, please consult the document below:

Laboratorios Farmacéuticos ROVI announces its financial results for the first nine months of 2023. The company closed the period with operating revenue of 594.9 million euros, EBITDA of 171.2 million euros and a net profit of 118.8 million euros.

The CDMO business, which is one of the pillars of ROVI’s business strategy, showed a 7% increase on the first nine months of 2022, totalling 287.6 million euros.

ROVI’s injectables manufacturing plants in Madrid, San Sebastián de los Reyes and Alcalá de Henares were approved by the FDA for the fill-and-finish of syringes with the messenger RNA COVID-19 vaccine. Thus, ROVI also expects to produce Moderna vaccines for supply in the United States.

Heparin division sales (low-molecular-weight and other heparins) dropped 10% to 181.7 million euros in the first nine months of 2023. This was due to the difference between the increase in the orders placed by partners in 2022 related to the treatment for COVID-19 and the lower volume of orders from partners in 2023.

Risperidone ISM® sales evolved favourably and totalled 9 million euros. This product showed growth of 27% in the third quarter of the year in comparison with the second quarter of 2023.

R&D investment rose to 16.5 million euros and was mainly linked to development of the phase I of Letrozole LEBE and the development of phase I of the new three-monthly formulation of Risperidone ISM®.

Regarding the process for marketing authorisation for Risperidone ISM® in the United States, the FDA has notified ROVI of the new user fee goal data, which will be 29 March 2024.

ROVI is again raising its operating revenue guidance for 2023 from a high-single-digit percentage decrease on 2022 to stable sales.

For 2024, ROVI expects its operating revenue to decrease by a mid-teen percentage in comparison with 2023. Notwithstanding, this guidance depends on factors the impact of which is difficult to estimate at present, such as:

• -Evolution of the demand and production in the 2024 COVID-19 vaccination campaign, since the 2023 campaign is still in progress;
• -Potentially obtaining new customers in the CDMO area, with the resulting impact on sales; and
• Potential sales of Risperidone ISM in the United States once it has received marketing authorisation from the FDA.